Results 21 to 30 of about 14,945 (175)
Inflammatory residual risk. An emerging target to reduce cardiovascular disease [PDF]
, 2018 Cardiovascular Residual Risk and Cardiovascular ...
Presta, Vivianne, Volpe, Massimo
core +1 more source
Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): An open-label, phase II study [PDF]
, 2016 OBJECTIVE: To evaluate the efficacy of canakinumab, a high-affinity human monoclonal anti-interleukin-1β antibody, in inducing complete or almost complete responses in patients with active tumour necrosis factor receptor-associated periodic syndrome ...
Abrams, Ken +9 more
core +1 more source
Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms [PDF]
, 2018 Hypertension and type 2 diabetes are common comorbidities. Hypertension is twice as frequent in patients with diabetes compared with those who do not have diabetes.
Guzik, Tomasz J. +2 more
core +1 more source
Efficacy of canakinumab in mild or severe COVID‐19 pneumonia
Immunity, Inflammation and Disease, 2021 Background Clinicians all around the world are currently experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Several therapeutic strategies have been used until now but, to date, there is no specific therapy to
Katia Falasca +9 more
doaj +1 more source
Interleukin-1 blockade in recently decompensated systolic heart failure: study design of the recently decompensated heart failure anakinra response trial (RED-HART) [PDF]
, 2015 Heart Failure (HF) is a clinical syndrome characterized by dyspnea, fatigue, and poor exercise capacity due to impaired cardiac function. The incidence of HF is increasing and represents the leading cause of hospitalization in the United States among ...
Abbate Antonio +8 more
core +1 more source
BMC Musculoskeletal Disorders, 2011 Background Canakinumab is a fully human anti-interleukin IL-1beta monoclonal antibody, being investigated for the treatment of rheumatoid arthritis (RA).
Arulmani Udayasankar +10 more
doaj +1 more source
Expedited Desensitization to Canakinumab
Allergy & Rhinology, 2020 Introduction Interleukin-1 (IL-1) antagonists have been successful in the management of monogenic auto-inflammatory diseases, notably classic hereditary fever syndromes, such as Familial Mediterranean Fever (FMF). Anakinra (Kineret®), a human recombinant
Neha Sanan DO +3 more
doaj +1 more source
Targeting inflammation to reduce cardiovascular disease risk [PDF]
, 2017 This joint themed section of the British Journal of Pharmacology and the British Journal of Clinical Pharmacology stems from a joint British Pharmacological Society – Italian Society of Pharmacology symposium held at the 37th National Congress of the ...
Cirino, Guiseppe, Maffia, Pasquale
core +1 more source
Frontiers in Medicine, 2023 IntroductionThe blockade of interleukine-1 (anakinra and canakinumab) is a well-known highly effective tool for monogenic autoinflammatory diseases (AIDs), such as familial Mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome,
Ekaterina Alexeeva +20 more
doaj +1 more source
Rilonacept and canakinumab [PDF]
British Journal of Clinical Pharmacology, 2011 Two new orphan medicines, rilonacept [1, 2] (Regeneron®) and canakinumab [3, 4] (Ilaris®), are indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS). CAPS occur in a group of rare, inherited, inflammatory diseases where patients have a mutation in the NLRP3 (nucleotide-binding domain, leucine-rich family, pyrin domain-containing-
Eline A, Dubois +2 more
openaire +2 more sources